東華大學圖書館 |

Neurophysiologic biomarkers in neuropsychiatric disorders = etiologic and treatment considerations /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Neurophysiologic biomarkers in neuropsychiatric disorders/ edited by Daniel C. Javitt, James C. McPartland.
其他題名:	etiologic and treatment considerations /
其他作者:	Javitt, Daniel C.
出版者:	Cham :Springer Nature Switzerland : : 2024.,
面頁冊數:	xxiii, 831 p. :ill. (chiefly color), digital ;24 cm.
內容註:	Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.
Contained By:	Springer Nature eBook
標題:	Biochemical markers. -
電子資源:	https://doi.org/10.1007/978-3-031-69491-2
ISBN:	9783031694912

Neurophysiologic biomarkers in neuropsychiatric disorders = etiologic and treatment considerations /
Neurophysiologic biomarkers in neuropsychiatric disordersetiologic and treatment considerations /[electronic resource] :edited by Daniel C. Javitt, James C. McPartland. - Cham :Springer Nature Switzerland :2024. - xxiii, 831 p. :ill. (chiefly color), digital ;24 cm. - Advances in neurobiology,v. 402190-5223 ;. - Advances in neurobiology ;v. 40..

Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.

This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.

ISBN: 9783031694912

Standard No.: 10.1007/978-3-031-69491-2doiSubjects--Topical Terms:

587592
Biochemical markers.

LC Class. No.: R853.B54

Dewey Class. No.: 610.28

Neurophysiologic biomarkers in neuropsychiatric disorders = etiologic and treatment considerations /
LDR:05142nmm a2200337 a 4500 001 2380704
003 DE-He213
005 20241120115339.0
006 m d
007 cr nn 008maaau
008 250418s2024 sz s 0 eng d
020 $a 9783031694912 $q (electronic bk.)
020 $a 9783031694905 $q (paper)
024 7 $a 10.1007/978-3-031-69491-2 $2 doi
035 $a 978-3-031-69491-2
040 $a GP $c GP
041 0 $a eng
050 4 $a R853.B54
072 7 $a MMH $2 bicssc
072 7 $a MED105000 $2 bisacsh
072 7 $a MKL $2 thema
082 0 4 $a 610.28 $2 23
090 $a R853.B54 $b N494 2024
245 0 0 $a Neurophysiologic biomarkers in neuropsychiatric disorders $h [electronic resource] : $b etiologic and treatment considerations / $c edited by Daniel C. Javitt, James C. McPartland.
260 $a Cham : $b Springer Nature Switzerland : $b Imprint: Springer, $c 2024.
300 $a xxiii, 831 p. : $b ill. (chiefly color), digital ; $c 24 cm.
490 1 $a Advances in neurobiology, $x 2190-5223 ; $v v. 40
505 0 $a Introduction to volume: Biomarkers in Psychiatry -- Part I: Government and Pharma perspectives on biomarker development -- Biomarker Methodologies: a NIMH Perspective -- Neural Circuitry-related biomarkers for drug development in psychiatry - An industry perspective -- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective -- Part II: Biomarker methodologies and Translational Approaches -- Methods for and use of functional magnetic resonance imaging in psychiatry -- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches -- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications -- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry -- Rodent models for ASD biomarker development -- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates -- Part III: Biomarkers in schizophrenia and clinical high risk -- Functional Connectivity Biomarkers in Schizophrenia -- The use of event-related potentials in the study of schizophrenia: An overview -- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here? -- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia -- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience -- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia -- Part IV: Biomarkers in ASD -- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG) -- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder -- Delineating a pathway for the discovery of functional connectome biomarkers of autism -- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process -- Part V: Other disorders -- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD -- Neuroimaging Biomarkers in Parkinson's Disease -- Biomarkers of Auditory-Verbal Hallucinations -- Part VI: Cross-diagnostic methodologies -- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes -- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence -- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders -- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.
520 $a This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson's disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.
650 0 $a Biochemical markers. $3 587592
650 0 $a Neurobehavioral disorders $x Treatment. $3 3597238
650 1 4 $a Psychiatry. $3 517037
650 2 4 $a Neuroscience. $3 917253
650 2 4 $a Neurology. $3 588698
650 2 4 $a Pharmacology. $3 634543
650 0 $a Neurobehavioral disorders. $3 753992
700 1 $a Javitt, Daniel C. $3 3734325
700 1 $a McPartland, James C. $3 2062367
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Advances in neurobiology ; $v v. 40. $3 3734326
856 4 0 $u https://doi.org/10.1007/978-3-031-69491-2
950 $a Biomedical and Life Sciences (SpringerNature-11642)